Experience

home office

• Graphic Design
• 100 - 200 Employee

• Retired

  • Mar 2022 - Present



Appaloosa Clinical Development LLC

• Newtown, PA

• President

  • Apr 2018 - Present

  Provide consultation to large, mid-size and emerging pharmaceutical and medical device companies regarding new applications, clinical development, clinical trial management, and regulatory interactions. Experience with Phase 1 through 4 trials, with greater than 35 years experience in hematology. Most recently involved in development and application of gene therapy for rare diseases. Provide consultation to large, mid-size and emerging pharmaceutical and medical device companies regarding new applications, clinical development, clinical trial management, and regulatory interactions. Experience with Phase 1 through 4 trials, with greater than 35 years experience in hematology. Most recently involved in development and application of gene therapy for rare diseases.



Virginia Commonwealth University

• United States
• Higher Education
• 700 & Above Employee

• Professor of Clinical Medicine

  • 2005 - Present

• Professor of Medicine, Pathology and Biomedical Engineering

  • Jun 1985 - Mar 2005



CSL Behring

• United States
• Biotechnology Research
• 700 & Above Employee

• Vice President of Researh and Development and Therapeutic Area

  • Jun 2019 - Mar 2023

  Develops and oversees the execution of the comprehensive TA Strategy for Haemostasis and Thrombosis. Responsible for building and maintaining a fully integrated and aligned TA team. Works with functional heads to ensure alignment of the TA portfolio with TA priorities. Responsible for leading the core Haemostasis and Thrombosis team to assure implementation and execution of the TA strategy. Develops and oversees the execution of the comprehensive TA Strategy for Haemostasis and Thrombosis. Responsible for building and maintaining a fully integrated and aligned TA team. Works with functional heads to ensure alignment of the TA portfolio with TA priorities. Responsible for leading the core Haemostasis and Thrombosis team to assure implementation and execution of the TA strategy.



Spark Therapeutics, Inc.

• United States
• Biotechnology
• 700 & Above Employee

• Head of Clinical Development

  • Aug 2016 - Mar 2023

  Provide medical and strategic input to clinical programs for gene therapy for hemophilia A and B. Participate in business development activities regarding future opportunities as well as provide medical and strategic input to future gene therapy indication targets approachable by delivery of therapeutic genes to hepatocytes. Provide medical and strategic input to clinical programs for gene therapy for hemophilia A and B. Participate in business development activities regarding future opportunities as well as provide medical and strategic input to future gene therapy indication targets approachable by delivery of therapeutic genes to hepatocytes.



Pfizer

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Vice President of Clinical Hematology

  • Jun 2010 - Jul 2016



US Army

• United States
• Armed Forces
• 700 & Above Employee

• Colonel

  • Mar 1987 - Mar 2010

  Commander of 4215th US Army Reserve Hospital on two occasions. Activated and served in Operations Desert Storm, Nobel Eagle, Joint Guardian, and Iraqi Freedom. Retired 2010. Commander of 4215th US Army Reserve Hospital on two occasions. Activated and served in Operations Desert Storm, Nobel Eagle, Joint Guardian, and Iraqi Freedom. Retired 2010.



Novo Nordisk Pharmaceuticals

• Executive Director

  • 2005 - 2010